Faruqi and Faruqui, LLP Logo
Share this page

Myriad Genetics, Inc. (MYGN)

NASDAQ:MYGN

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Myriad Genetics, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ:MYGN) of the June 19, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Myriad stock or options between August 13, 2014 and March 12, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/MYGN.  There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of all those who purchased Myriad securities between August 13, 2014 and March 12, 2018 (the “Class Period”).  The case, Kessman v. Myriad Genetics et al, No. 18-cv-00336 was filed on April 20, 2018, and has been assigned to Judge Paul M. Warner.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that the Company was filing improper payment claims under Medicare and Medicaid for its hereditary cancer testing.

Specifically, on March 12, 2018, the Company filed a Form 8-K with the Securities and Exchange Commission, disclosing that “[t]he Company recently received a Subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid.”  The Company further stated that the “Subpoena requested that the Company produce documents relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.”

After the announcement, Myriad’s share price fell from $33.02 per share on March 12, 2018 to a closing price of $29.01 on March 13, 2018—a $4.01 or a 12.1% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Myriad Genetics, Inc. (MYGN)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 03/19/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.